PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

PRTC 11.05.2024

Full Press ReleaseSEC FilingsOur PRTC Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - PureTech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.09.2025 - PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
  • 01.08.2025 - PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 12.16.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.16.2024 - EX-99.1 EX-99.1
PDF Version
RNS Number : 9167K
PureTech Health PLC
05 November 2024

5 November 2024

PureTech Health plc

PureTech Founded EntitySeaport Therapeutics NamesLauren Whiteas Chief Financial Officer

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations

PureTech Health plc(Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity,Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team,today announced the appointment ofLauren Whiteas Chief Financial Officer. An accomplished biotech financial executive,Ms. Whitemost recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE: ABBV) for$10.1 billionin 2024.

The full text of the announcement from Seaport is as follows:

Seaport Therapeutics NamesLauren Whiteas Chief Financial Officer

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations

BOSTON,November 5, 2024-Seaport Therapeutics("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment ofLauren Whiteas Chief Financial Officer. An accomplished biotech financial executive,Ms. Whitemost recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE: ABBV) for$10.1 billionin 2024.

"I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatment of anxiety, depression and other neuropsychiatric disorders," saidDaphne Zohar, Founder and Chief Executive Officer at Seaport. "Her strong leadership background in biotech finance will be valuable as we chart an efficient path to delivering these important new medicines to patients."

Ms. Whitebrings over 22 years of corporate finance, accounting, strategic partnering and investor relations expertise to Seaport. As the CFO at ImmunoGen,Ms. Whiteplayed a key role on the internal deal team, conducting thorough analysis and due diligence during the M&A process with multiple potential buyers, which ultimately led to the successful acquisition of the company by AbbVie. Additionally,Ms. Whitehelped to maximize the successful commercial launch of ELAHERE®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before joining ImmunoGen,Ms. Whiteserved as Chief Financial Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics (NASDAQ: CCCC), where she was responsible for developing and leading the company's financial, capital, and procurement strategies.

Prior to that,Ms. Whiteheld roles of increasing responsibility at Novartis (NYSE: NVS), most recently serving as Global Head of Financial Planning and Analysis for theNovartis Institutes for BioMedical Research(NIBR), where she drove financial strategy and business planning. Before Novartis,Ms. Whiteheld strategy and marketing roles withBoston Consulting Group and General Electric.Ms. Whitereceived a BS from theCarroll Schoolof Management atBoston Collegeand earned an MBA fromHarvard Business School.

"I'm excited to join the outstanding team at Seaport at this important stage of development," saidMs. White. "I look forward to working with our team and collaborators to leverage our recent financial progress and support Seaport's mission to deliver meaningful medicines that positively impact the lives of patients and their families."

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visitwww.seaporttx.com.

AboutPureTech Health

PureTechis a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities.PureTech'sR&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by theU.S. Food and Drug Administration. A number of these programs are being advanced byPureTechor its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by thePureTechteam through key validation points.

For more information, visitwww.puretechhealth.comor connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Seaport's development plans for its pipeline of therapeutics for the treatment of depression, anxiety and other neuropsychiatric disorders, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year endedDecember 31, 2023, filed with theSECand in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com

InvestorRelations

IR@puretechhealth.com

UK/EU Media

Ben Atwell,Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com

US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of theLondon Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.

END

NRAGGBDBIXGDGSU

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com